Fig. 1.
![Fig. 1. (A) Surface expression of HLA class I, HLA class II, and CD80, CD86, and CD34 molecules on untreated AML cells and AML cells cultured with GM-CSF, IL-4, and TNF-. I, No MoAb; II, anti-CD80; III, anti-CD86; IV, anti-DR; V, anticlass I; VI, CD34. Cells were labeled with fluorescein-conjugated MoAbs and analyzed on a FACS. (B) Proliferative responses of hsp65 (aa418-427)-specific T-cell clone R2F10 and HLA-DR13-specific alloreactive clone against untreated or cytokine treated (72 hours) AML cells. Antigens (hsp65, 5μg/mL; and hsp65 peptide 418-427, 1 μg/mL) were added in the assay. The results are expressed as stimulation index (cpm in the presence of stimulator [APC]-cpm in the absence of stimulator/cpm in the absence of the stimulator).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/92/5/10.1182_blood.v92.5.1677/4/blod41714001x.jpeg?Expires=1735850166&Signature=dF-voWMuTJnwko3S-c53I4NVpb84roOGkllG6N97kAfScBcBRoXttFqIgyjrVLiNQCqC80V0toZLI1JiaLDLQJUqj4eOH4JuUwuft6vclTOyY3o9KK9bF9SjvvK~LOuDHhHud1lI2ukPfiBIgxoy31AuniRHMhEonWT-s4fPASqQhNp~S2FppF~XPYr4oDlX5gzqAo5e-Fj0q6Mgjgk-VR7ucVRi3hO23ClVqzlL6tDU7daqgqB13~Ud7zraQcm2Mx7jmVZSHlaXQb3KgND98oVcRjZRWLLEPXGYT3jrflkmM09pl-eRambfbzmyEF280m~-BJ53kCxQUqTEZIeCdg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
(A) Surface expression of HLA class I, HLA class II, and CD80, CD86, and CD34 molecules on untreated AML cells and AML cells cultured with GM-CSF, IL-4, and TNF-. I, No MoAb; II, anti-CD80; III, anti-CD86; IV, anti-DR; V, anticlass I; VI, CD34. Cells were labeled with fluorescein-conjugated MoAbs and analyzed on a FACS. (B) Proliferative responses of hsp65 (aa418-427)-specific T-cell clone R2F10 and HLA-DR13-specific alloreactive clone against untreated or cytokine treated (72 hours) AML cells. Antigens (hsp65, 5μg/mL; and hsp65 peptide 418-427, 1 μg/mL) were added in the assay. The results are expressed as stimulation index (cpm in the presence of stimulator [APC]-cpm in the absence of stimulator/cpm in the absence of the stimulator).
